Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$5.51 – $5.81
Volume5,398
Market cap$537M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for VALN.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for VALN.
Recent news
Company coverage with links to the original publishers.
Valneva reported positive long-term antibody persistence data for its chikungunya vaccine IXCHIQ®, with 94% of participants maintaining neutralizing antibody levels five years after a single dose. The persistence was comparable across age groups (18-64 years and 65+ years), supporting the vaccine's differentiated profile for a disease with unpredictable epidemic outbreaks. The company continues to generate real-world evidence through post-commercialization studies, including a pilot vaccination campaign in Brazil that vaccinated approximately 80,000 adults.
Pfizer stock surged nearly 14% in August following better-than-expected Q2 earnings (revenue $15B vs. $14.4B expected, EPS $0.77 vs. $0.68 expected) and raised full-year revenue guidance. The company also achieved regulatory victories with EMA validation for a Lyme disease treatment and FDA approval for an updated COVID vaccine. Despite investor impatience over the lack of new blockbuster products, the analyst views Pfizer as undervalued with a promising pipeline from recent acquisitions.
Valneva SE reported Q1 2026 financial results with total product sales of €30.5 million and a cash position of €105.3 million as of end March 2026, excluding proceeds from a successful reserved offering completed in April 2026. The company announced participation in U.S. and European investor conferences in June 2026.
Valneva SE reported its share capital composition as of May 31, 2026, with 189.77 million ordinary shares and double voting rights on 1,859 shares. The company also announced Q1 2026 financial results showing product sales of €30.5 million and a cash position of €105.3 million as of end March 2026, excluding proceeds from an April reserved offering.
Pfizer and Valneva announced that their Lyme disease vaccine candidate PF-07307405 (LB6V) demonstrated over 70% efficacy in preventing Lyme disease in individuals aged five years and older in Phase 3 VALOR trial. The vaccine candidate was well-tolerated.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.